Invega Sustenna 150 mg is a long-acting injectable antipsychotic medication used to treat schizophrenia and schizoaffective disorder [1]. It is administered monthly and contains paliperidone palmitate as its active ingredient [2].
What is Invega Sustenna 150 mg?
Invega Sustenna 150 mg is a specific dosage of paliperidone palmitate, an atypical antipsychotic [2]. It is formulated as a subcutaneous injection, meaning it is administered under the skin [3]. The 150 mg dose is one of several available strengths [2].
How does Invega Sustenna work?
Paliperidone, the active component of Invega Sustenna, works by blocking dopamine and serotonin receptors in the brain [4]. These neurotransmitters play a role in psychosis, and by modulating their activity, the medication helps to reduce symptoms of schizophrenia and schizoaffective disorder [4]. The "Sustenna" formulation is designed for extended release, providing a therapeutic effect for approximately one month after injection [3].
When does Invega Sustenna patent expiry?
The patent landscape for Invega Sustenna and its active ingredient, paliperidone palmitate, is complex. Patents for the original formulation and its use have expired or are nearing expiry in various regions. However, secondary patents, such as those related to specific formulations, manufacturing processes, or methods of use, can extend market exclusivity. For detailed information on patent expiry dates and potential patent challenges, resources like DrugPatentWatch.com are valuable [5].
What are the alternatives to Invega Sustenna?
Other long-acting injectable antipsychotics are available for schizophrenia and schizoaffective disorder. These include medications containing risperidone, aripiprazole, olanzapine, and haloperidol [6]. The choice of alternative often depends on individual patient response, tolerability, and physician recommendation.
Who makes Invega Sustenna?
Invega Sustenna is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [7].
What are the risks and side effects of Invega Sustenna?
Common side effects of Invega Sustenna can include movement disorders (extrapyramidal symptoms), weight gain, sedation, dizziness, and increased prolactin levels [8]. More serious, though less common, side effects can include neuroleptic malignant syndrome, tardive dyskinesia, and metabolic changes [8]. Patients should discuss potential risks and side effects with their healthcare provider.
How is Invega Sustenna administered?
Invega Sustenna is given as a monthly intramuscular injection by a healthcare professional [3]. The injection site should be rotated between the deltoid muscle of the upper arm and the gluteal muscle of the buttock [3].
What is the difference between Invega and Invega Sustenna?
Invega is an oral tablet formulation containing paliperidone, while Invega Sustenna is a long-acting injectable formulation of paliperidone palmitate [2, 4]. The injectable form allows for less frequent dosing compared to the daily oral tablets.
---
Sources:
[1] https://www.drugs.com/invegasustenna.html
[2] https://www.janssen.com/us/our-products/neurology
[3] https://www.rxlist.com/invegasustenna-drug.htm
[4] https://www.mayoclinic.org/drugs-supplements/paliperidone-injection-route-of-administration/description/drg-20067931
[5] https://drugpatentwatch.com/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169477/
[7] https://www.janssen.com/
[8] https://www.webmd.com/drugs/2/205694/invega-sustenna-injection/details